ipharmacenter Consulting services

The U.S. FDA has approved Foundayo (orforglipron), a once‑daily GLP‑1 tablet for chronic weight management in adults with obesity or overweight and weight‑related comorbidities. It is currently the only GLP‑1 pill for weight loss that can be taken at any time of day without specific restrictions on food or water intake. Also read: New Hope for GVHD Patients as Rezurock Wins EU Approval Backed by the phase 3 ATTAIN programme, Foundayo delivered clinically meaningful and sustai

China’s National Medical Products Administration (NMPA) has authorised Exdensur (depemokimab) as an add-on maintenance therapy for severe asthma with an eosinophilic phenotype in adults and adolescents aged 12 years and older. This decision makes Exdensur the first ultra-long-acting biologic available in China for this patient population, offering a new option for those whose disease remains uncontrolled despite standard treatment. Details of Phase III SWIFT-1 and SWIFT-2 tri

The European Commission has granted conditional marketing authorisation for Sanofi’s Rezurock (belumosudil) to treat chronic graft-versus-host disease (GVHD) in adults and adolescents aged 12 years and older who weigh at least 40 kg. The approval offers a critical treatment option for patients who have limited benefit from current therapies or have exhausted existing options. Also read: Top 10 Pharmaceutical Companies by Revenue 2025 The decision is supported by evidence from